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Abstract 
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Type 2 diabetes mellitus is characterized by elevated plasma glucose levels 
arising from increased peripheral insulin resistance and impaired insulin secretion.  
Free fatty acids (FFAs) serve not only as nutrients but also as cell signaling mediators, 
and they are implicated in several metabolic disorders including diabetes. Elevated 
circulating FFAs cause insulin resistance and impair glucose metabolism in the liver, 
muscle, adipose tissue, and pancreatic β-cells. GPR40/FFAR1 was identified as a 
receptor for medium- and long-chain FFAs and was preferentially expressed at high 
levels in the pancreatic β-cells. GPR40/FFAR1 leads to glucose dependent augmentation 
of insulin secretion in vitro, whereas the function of GPR40/FFAR1 in vivo was not 
clarified. In this study, I performed studies on the physiological role of GPR40/FFAR1 
with genetically modified animals to whether or not loss and overexpression of 
GPR40/FFAR1 exacerbates diabetes, that is, whether GPR40 has a significant 
pathophysiological role in the development of diabetes or not. 
In the first chapter, I describe the phenotypic analysis of GPR40/FFAR1 
knockout mice (KO). GPR40/FFAR1 KO mice developed glucose intolerance to a 
similar degree as GPR40/FFAR1 wild-type (WT) mice on a high-fat diet condition and 
diabetogenic KK gene background, so the lack of GPR40/FFAR1 does not exacerbate 
glucose intolerance and insulin resistance. Glucose-induced insulin secretion under high 
palmitate concentration was significantly lower in the pancreatic islets of KO mice than 
those of WT mice, so GPR40/FFAR1 has a major role in regulating fatty-acid-mediated 
insulin secretion. These findings indicate that loss of GPR40/FFAR1 function does not 
contribute to induce or exacerbate diabetes, and especially GPR40/FFAR1 is selectively 
involved in fatty-acid-augmented insulin secretion. 
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In the second chapter, I describe the phenotypic analysis of GPR40/FFAR1 
overexpressed mice, named GPR40/FFAR1 transgenic (Tg) mice. In comparison with 
nontransgenic (NonTg) littermates, GPR40/FFAR1-Tg mice resulted in improved 
glucose tolerance with augmented insulin secretion on a high-fat diet condition and 
diabetogenic KK gene background. Isolated islets from hGPR40/FFAR1-Tg mice 
enhanced insulin secretion in response to high glucose than those from NonTg mice 
with unchanged low glucose stimulated insulin secretion. In addition, insulin secretion 
in hGPR40/FFAR1-Tg islets significantly increased insulin secretion against palmitate 
in the presence of glucose. These results indicate that GPR40/FFAR1 has a role in 
regulating glucose-stimulated insulin secretion in vitro and plasma glucose levels in 
vivo.  
Taken together, I conclude that GPR40/FFAR1 is concerned with overt increase 
in insulin secretion in the presence of elevated glucose such as during the postprandial 
period, and there data supported the concept that GPR40/FFAR1 agonists might be 
effective insulin secretagogues for the treatment of type 2 diabetes with low risk of 
hypoglycemia. 
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AUC  area under the curve 
BSA  bovine serum albumin 
DAG  diacylglycerol 
DPP-IV  dipeptidyl peptidase-4 
ELISA  enzyme-linked immunosorbent assay 
ES  embryonic stem 
FBS  fetal bovine serum  
FFAs  free fatty acids  
GIP  glucose-dependent insulinotropic polypeptide  
GLP-1  glucagon-like peptide-1 
GPR40/FFAR1  G-protein coupled receptor 40/free fatty acid receptor 1 
GSIS  glucose stimulated insulin secretion 
HbA1c  hemoglobin a1c 
HBSS  Hanks' Balanced Salt Solution 
HE  heterozygote 
HFD  high-fat diet 
HOMA-IR homeostatic model assessment of insulin ressitance 
IP3  inositol 1, 4, 5-triphosphate  
KO  knockout  
KRBH  Krebs-Ringer biocarbonate buffer  
NEFA  non-esterified fatty acids 
NonTg  nontransgenic 
PCR  polymerase chain reaction 
PKC  protein kinase C 
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PLC  phosholipase C 
PPAR-γ  peroxisome proliferator-activated receptor-γ 
SGLT2  sodium dependent-glucose cotransporter 2 
Tg  transgenic 
WT  wild-type  
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General Introduction 
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Why the treatments for diabetes are needed? 
 
There is nothing irreplaceable other than health for us at any age. One of the 
things that support our health is medicine to care disease. Today, the number of patients 
in infectious diseases such as tuberculosis and dysentery decreased, so mortality rate of 
infants was significantly reduced. In addition to the fact that nutritional status and 
hygiene environment was dramatically improved, it is likely that good medicine has 
been developed recently and medical technology has advanced rapidly.  
Diabetes is one of the diseases that plague many people even in the modern 
disease. By recent report of the International Diabetes Federation, 382 million people 
have diabetes (1) and the number of people with diabetes is increasing in every country 
year by year, and this will rise to 592 million people by 2035 (Figure 1) (1). The World 
Health Organization (WHO) reported that diabetes mellitus is the eight-leading cause of 
death worldwide (Figure 2). 
 
 
 
 
 
 
 
 
Figure 1. Diabetes is a huge and growing problem in the worldwide.  
The data was cited from the reference (1). 
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Figure 2. The top 10 causes of death worldwide in 2012. 
The data on the 10 leading causes of death in the world was cited from WHO website 
(http://www.who.int/mediacentre/factsheets/fs310/en/) 
 
Type 2 diabetes is the most common type of diabetes. It usually occurs in 
adults, but the number of patients is increasingly seen in children and adolescents. Type 
2 diabetes mellitus is characterized by elevated plasma glucose levels arising from 
increased peripheral insulin resistance and impaired insulin secretion (2). Many people 
are able to manage their condition through a healthy diet, increased physical activity, 
and oral medication. The number of type 2 diabetes patients is growing rapidly 
worldwide. This rise is associated with economic development, aging populations, 
increasing urbanisation, dietary changes, reduced physical activity, and changes in other 
lifestyle patterns (3). Chronic hyperglycemia contributes to the complications associated 
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with type 2 diabetes (4), such as cardiovascular disease, kidney disease (diabetic 
nephropathy), and eye disease (diabetic retinopathy) (Figure 3). Especially, ischemic 
heart disease was the leading cause of death worldwide by the World Health 
Organization (WHO) (Figure 2). Patients with diabetes had greater risk of dying from 
cardiovascular disease and ischemic heart disease compared with people without 
diabetes. Risk of death increased through the range of HbA1c concentrations, with 
lowest rates in those with HbA1c concentrations less than 5% and a gradient of 
increasing rates through the whole distribution, so HbA1c levels correlate with 
cardiovascular mortality (5). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Major diabetes complications.  
The data was cited from the reference (1). 
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Current status of therapeutics for type 2 diabetes 
 
Conventional treatments of type 2 diabetes are primarily directed at reducing 
the demand for insulin and decreasing peripheral resistance by dietary management and 
physical exercise. In case the patients discontinue the lifestyle modification, medical 
therapy for type 2 diabetes is needed. 
Biguanides, known as metformin, decreases glucose production in the liver and 
stimulates glucose uptake into peripheral tissues (6), and is a first line therapy for type 2 
diabetes.Thiazolidinedione derivative is an insulin sensitizer agent that selectively binds 
to peroxisome proliferator-activated receptor-γ (PPAR-γ) and activates it. 
Thiazolidinedione derivative decreases plasma glucose by increasing insulin sensitivity 
in the liver, the muscle, and the adipose tissue, and decreases hepatic glucose production 
(7). Alpha-glucosidase inhibitors are used for the treatment of diabetes in Japan mainly. 
They reversibly inhibit enzymatic cleavage of complex carbohydrates to simple 
absorbable sugars, and slow the absorption of carbohydrate from the small intestine and 
lower postprandial hyperglycemia (8). They are frequently applied to patients with mild 
diabetes mellitus and impaired glucose tolerance (9-11). Dipeptidyl peptidase-4 
(DPP-IV) inhibitor (12-14), has been demonstrated to improve glucose control in 
patients with type 2 diabetes (15, 16). The serine protease DPP-IV presents as the 
integral membrane form in a variety of organs and a soluble form in the circulation, and 
converts active forms of insulin-enhancing peptides glucagon-like peptide-1 (GLP-1) 
and glucose-dependent insulinotropic polypeptide (GIP) to inactive forms (17, 18). 
Thus, DPP-IV inhibition is associated with increased plasma levels of active forms of 
GLP-1 and GIP, thereby enhancing insulin secretion from pancreatic β-cells. Sodium 
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dependent-glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral drugs for 
the treatment of type 2 diabetes mellitus. They inhibit glucose re-absorption in the 
proximal renal tubules in the kidney providing insulin independent mechanism to lower 
plasma glucose levels (19). 
Drugs that enhance insulin secretion, such as sulfonylureas and nateglinides, 
are commonly used for the treatment of type 2 diabetes (20). However, these drugs 
enhance insulin secretion by direct closure of the KATP channel independent of plasma 
glucose levels, thereby causing hypoglycemia (21).  
There are many medicines for the treatment for type 2 diabetes, but each of 
them have specific adverse effects. Therefore, patients with diabetes would benefit 
from the development of a novel anti-diabetic drug that has a low hypoglycemia risk 
and improves plasma glucose levels. 
 
 
 
 
 
 
 
 
 
 
Figure 4. Pathology of anti-diabetic medicine 
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The function of free fatty acids 
 
Free fatty acids (FFAs) are not only energy sources, but also have pleiotropic 
effects in various tissues. In pancreatic β-cells, FFAs are well known to enhance insulin 
secretion in the presence of elevated plasma glucose levels (22, 23). Plasma 
concentrations of FFAs are elevated in the fasted state, and they play a role in the 
enhancement of the postprandial insulin response in vivo (24, 25)  
 
GPR40/FFAR1 as a novel drug target for type 2 diabetes 
 
G-protein coupled receptor 40/free fatty acid receptor 1 (GPR40/FFAR1) was 
identified as a receptor for medium- and long-chain FFAs and was preferentially 
expressed at high levels in pancreatic β-cells (26-31). Several reports have shown that 
GPR40/FFAR1 is mainly coupled with Gαq/Gα11, which activates phosholipase C (PLC) 
resulting in the formation of inositol 1, 4, 5-triphosphate (IP3) and induction of calcium 
release from endoplasmic reticulum (29, 32-34). In fact, FFAs increase intracellular 
calcium concentration via GPR40/FFAR1 and lead to glucose dependent augmentation 
of insulin secretion (21-24, 28, 30). Therefore, GPR40/FFAR1 agonist is a promissing 
candidate of new drug for the treatment of type 2 diabetes. Although several 
insulinotoropic drugs are used in clinical, such as sulfonylureas, DPP-IV inhibitors, and 
GLP-1 analogues, the signaling pathway activated by them in pancreatic β-cells is 
different from that induced by stimulation of GPR40/FFAR1. In the process of drug 
discovery of GPR40/FFAR1 agonist, I needed to clarify the function of GPR40/FFAR1 
in vivo, so I generated transgenic mice overexpressing the human GPR40/FFAR1 gene 
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and knockout mice to delete GPR40/FFAR1 gene function. One reason of generating 
transgenic and knockout mice was to examine the function of GPR40/FFAR1 in the 
whole body, not in vitro. Another reason of it was to examine the specific action of 
GPR40/FFAR1 in vivo, because the drug might have nonspecific action in vivo.  
  
 
 
 
 
 
 
 
 
Figure 5. Presumed mechanism of insulin secretion via GPR40 in pancreatic beta 
cell 
PLC, phospholipase C; IP3, inositol triphosphate; DAG, diacylglycerol; PKC, protein 
kinase C 
  
Objective of this research 
 
To clarify whether loss of function of GPR40/FFAR1 exacerbates diabetes or 
not, I have generated GPR40/FFAR1 knockout mice and examined their phenotypes in 
vitro and in vivo under high-fat diet feeding in chapter 1. Moreover, to clarify the 
function of GPR40/FFAR1 in pancreatic β-cells more extensively, I generated transgenic 
15 
 
mice, hGPR40/FFAR1-Tg, overexpressing the human GPR40/FFAR1 gene under control 
of the insulin II promoter and examined the role of GPR40/FFAR1 in the regulation of 
insulin secretion and glucose homeostasis in chapter 2. 
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Chapter 1: 
Lack of GPR40/FFAR1 Does not Induce Diabetes even under Insulin 
Resistance Condition 
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Abstract 
 
Background: G protein-coupled receptor/free fatty acid receptor 1 (GPR40/FFAR1) 
regulates free fatty acid-induced insulin secretion. This study has been performed to 
clarify whether or not loss of GPR40/FFAR1 function exacerbates diabetes, that is, 
whether GPR40 has an essential physiological role in the development of diabetes or 
not. 
Methods: I generated GPR40/FFAR1-knockout (KO) mice and analyzed their 
phenotypes in vitro and in vivo under the condition of dietary or genetically-induced 
insulin resistance.  
Results: GPR40/FFAR1 KO mice kept on a high-fat diet became obese, developed 
glucose intolerance to a similar degree as GPR40/FFAR1 wild-type (WT) mice. In 
addition, the phenotype of KO mice harboring diabetogenic KK background genes 
showed glucose intolerance at a level similar to level for control KK mice. In both 
mouse models with insulin resistance, insulin secretion after oral glucose load and 
HOMA-IR did not change between GPR40/FFAR1 KO and WT mice. Although 
glucose-induced insulin secretion under high palmitate concentration was significantly 
lower in KO than in WT islets, pancreatic insulin content and insulin secretion 
stimulated with glucose alone were not different between KO and WT mice. 
Conclusions: GPR40/FFAR1 has a major role in regulating fatty-acid-mediated insulin 
secretion, but the lack of GPR40/FFAR1 does not exacerbate glucose intolerance or 
insulin resistance induced by high-fat diet or diabetogenic KK gene. These findings 
indicate that loss of GPR40/FFAR1 function does not play an important role in inducing 
or exacerbating diabetes.  
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Introduction 
 
Free fatty acids (FFAs) are not only energy sources, but also have pleiotropic 
effects in various tissues. In pancreatic β-cells, FFAs are well known to enhance insulin 
secretion in the presence of elevated glucose (22, 23). GPR40/FFAR1 was identified as a 
receptor for medium- and long-chain FFAs, highly expressed in rodent primary β-cells, 
β-cell lines (26, 27, 29, 35), and human islets (30, 31). Several reports have shown that 
GPR40/FFAR1 is mainly coupled with Gαq, and the ligands stimulate phospholipase C 
(PLC), resulting in the formation of inositol 1, 4, 5-triphosphate (IP3) and induction of 
calcium release from endoplasmic reticulum (29, 32-34). In pancreatic β-cells, these 
signal cascades enhance intracellular calcium concentrations and augment 
glucose-stimulated insulin secretion (GSIS) (26, 27, 29, 33, 35, 36). Recent studies have 
shown that acute treatment by small-molecule agonists of GPR40/FFAR1 enhanced 
GSIS and improved postprandial glucose tolerance (37-39). Together with these 
findings, my previous results have confirmed that transgenic mice overexpressing 
human GPR40/FFAR1 in pancreatic β-cells exhibit improved glucose tolerance and 
enhanced GSIS (40). Furthermore, Tsujihata et al also have reported that TAK-875, an 
orally available GPR40/FFAR1 agonist, improves not only postprandial but also fasting 
hyperglycemia, without affecting normoglycemia (41). These studies indicate that 
pharmacological activation of GPR40/FFAR1 would have great potential as a novel 
treatment of type 2 diabetes. 
On the other hand, many preclinical studies suggest that prolonged exposure to 
elevated levels of fatty acids cause insulin resistance and pancreatic β-cell dysfunction, 
both of which promote type 2 diabetes (2, 42-44). Although one group has reported that 
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GPR40/FFAR1 knockout mice fed with a high-fat diet protected hyperinsulinemia, 
hepatic steatosis, and impaired glucose homeostasis (45), the studies in the independent 
strains of GPR40/FFAR1 knockout mice did not reproduce a role for GPR40/FFAR1 in 
high-fat-diet-induced insulin resistance or hepatic steatosis (46-49).  
To clarify whether loss of function of GPR40/FFAR1 exacerbates diabetes or 
not, I have generated GPR40/FFAR1 knockout mice and examined their phenotypes in 
vitro and in vivo under high-fat-diet feeding. I also investigated their phenotypes by 
introducing the diabetogenic polygene, KK (50-52), into the knockout mice. These 
findings indicate that GPR40/FFAR1 has a major role in regulating fatty-acid-mediated 
insulin secretion, but does not exacerbate high-fat-diet and diabetogenic KK-induced 
glucose intolerance and insulin resistance. 
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Materials and Methods 
 
Animals  
GPR40/FFAR1 knockout mice were generated by homologous recombination in 
embryonic stem (ES) cells as described below. The mouse GPR40/FFAR1 gene was 
derived from the mouse 129SvJBAC genomic library (Invitrogen, Carlsbad, CA, USA), 
and construction of mouse GPR40/FFAR1 gene targeting vector was carried out by 
inserting 11.1 kbp of the 5’ downstream arm and 3.5 kbp of the 3’ downstream arm into 
the vector harboring neomycin-resistant gene expression unit (Figure 6A). I transfected 
targeting vectors into ES cells (AB2.2 prime, Lexicon Genetics Incorporated, Texas, 
USA). The homologous recombinant was identified by Southern blot analyses (Figure 
6B). The cells were injected into the eight-cell stage embryos from C57BL/6 mice and 
transferred into pseudopregnant ICR mouse females to generate chimeric mice. Male 
chimeric mice with agouti coat color were mated with C57BL/6 female mice to generate 
heterozygote mice. After crossing with heterozygote mice, the homozygotes were 
identified by PCR of tail DNAs using the mouse GPR40/FFAR1 gene specific primers 
(5’-CAGCCAGTCCCTTCCCGCTTCA-3’and 
5’-GCAGGTCCGAAATGGTCAGGTTTAGCA-3’) (Figure 6C). After confirmation 
of the lack of mouse GPR40/FFAR1 gene expression (Figure 6D), the obtained 
GPR40/FFAR1 KO mice were maintained by backcrossing with C57BL/6J mice more 
than five generations, and the GPR40/FFAR1 KO mice were identified by PCR analyses 
described as above. When examining the GPR40/FFAR1 KO mice in genetically diabetic 
condition, the backcrossed GPR40/FFAR1 KO mice were mated with mice harboring a 
KK background. The resulted heterozygote littermates harboring KK background were 
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further inter-crossed, and the genotype of the obtained pups were determined by PCR of 
tail DNAs. Then, the resultant mice were used for further experiments as wild-type mice 
(WT x KK) and GPR40/FFAR1 KO mice (KO x KK) contained almost 50% KK 
background. The almost age- and sex-matched wild-type littermates were used as 
control mice throughout the study, and all experiments were conducted using male mice. 
The mice were fed with a regular diet CE-2 containing 11.5 kcal% fat (CLEA Japan 
Inc.), and were housed in colony cages and maintained on a 12-hr/12-hr light-dark cycle 
with freely access to water and food. For examination of the effects of a high-fat diet, 
mice were fed with a high-fat diet containing 60 kcal% fat (D12492, Research Diets Inc., 
New Brunswick, NJ, USA) or a low-fat diet containing 10 kcal% fat (D12450B, 
Research Diets Inc.) from 8 weeks of age. Plasma glucose levels were automatically 
analyzed by Dri-Chem (FujiFilm Medical, Tokyo, Japan), and plasma nonesterified fatty 
acids (NEFAs) were determined using a Wako test (Wako Pure Chemical Industries, 
Osaka, Japan). Plasma insulin levels were measured by enzyme-linked immunosorbent 
assay (Morinaga Institute of Biological Science, Tokyo, Japan). Plasma leptin levels 
were measured by ELISA (Mouse Leptin Quantikine(R) ELISA Kit, R&D systems Inc., 
Minneapolis, USA). To evaluate the degree of insulin resistance, we calculated the 
homeostasis model assessment-insulin resistance (HOMA-IR, fasted insulin 
(μU/ml)×fasted glucose (mmol/l)/22.5) (53). All procedures were conducted according 
to the Experimental Animal Care Use Committee of Takeda Pharmaceutical Company 
Ltd.  
 
Oral glucose tolerance test  
Mice were orally administered glucose at a dose of 1 g/kg body weight after an 
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overnight fast. Blood samples were obtained at time 0 (just before glucose load), 7.5, 15, 
30, 60, and 120 min after glucose administration, followed by plasma preparation by 
centrifugation. Plasma glucose and insulin levels were measured as described above. 
 
Preparation of islets  
Islets were isolated from pancreas by collagenase digestion (54). The solution 
of 183 units/mg/kg collagenase (Wako Pure Chemical Industries Ltd.) dissolved in 
Hanks' Balanced Salt Solution (HBSS; Invitrogen, Carlsbad, CA, USA) containing 10 
μg/ml DNase I (Roche Diagnostics, Indianapolis, IN, USA) and 0.2% bovine serum 
albumin (BSA; Wako Pure Chemical Industries Ltd.), was injected into the common 
bile duct. The pancreas was removed and incubated at 37°C for 20 min, and washed 3 
times with HBSS, and islets were hand-collected under a microscope. For insulin 
secretion experiments, purified islets were used after overnight culture in RPMI 1640 
medium containing 5.5 mmol/l glucose and 10% fetal bovine serum (FBS) in a 
humidified atmosphere containing 5% CO2/95% air at 37°C. 
 
Insulin secretion assay  
A group of five islets was preincubated in Krebs-Ringer biocarbonate buffer 
(KRBH) containing 0.2% BSA and 1 mmol/l glucose for 30 min at 37°C, and then 
incubated for another 1 hr in KRBH containing glucose. For examination of the effect 
of fatty acids, sodium palmitate (CHEM SERVICE Inc., West Chester, PA, USA) was 
conjugated with FFA-free BSA (SIGMA ALDRICH Inc., St. Louis, MO, USA) at final 
palmitate and BSA concentrations of 1 mmol/l and 1.3%, respectively. The conjugated 
palmitate was added to KRBH containing 11 mmol/l glucose, and incubated for 1hr. At 
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the end of the incubation period, the amount of insulin in the culture supernatant was 
determined with ELISA as described above. Residual islets were sonicated and used to 
determine the DNA content (Quant-iT Picogreen dsDNA Assay Kit, Invitrogen). 
 
Measurement of pancreatic insulin content  
The pancreas was isolated and homogenized in acid–ethanol containing 74% 
ethanol with 0.15 mol/l HCl for the determination of insulin concentrations. The 
homogenized tissues were extracted overnight at 4°C and centrifuged at 12,000 g for 10 
min. The resultant supernatants were then diluted with phosphate-buffered saline 
containing 0.1% (wt/vol) bovine serum albumin, and the insulin levels in the 
supernatants were determined with ELISA as described above. 
 
Immunohistochemistry of pancreas  
Formalin-fixed, paraffin-embedded tissue sections (thickness of 4 μm) of the 
pancreas were immunostained using the avidin-biotin detection system (Ventana 
Medical Systems, Tucson, AZ, USA) and M.O.M. Immunodetection Kit (VECTOR 
Laboratories, Inc., Burlingame, CA, USA), according to the manufacturer’s instructions, 
and counterstained with haematoxylin. Anti-insulin antibody (1:200, MP Biomedicals 
Inc., Irvine, CA, USA), anti-glucagon antibody (1:2, ZYMED, South San Francisco, CA, 
USA), anti-glucose transporter 2 (GLUT2) antibody (1:200, CHEMICON International 
Inc., Temecula, CA, USA), and anti-proinsulin antibody (ready-to-use, Lab Vision, 
Fremont, CA, USA) were used as primary antibodies. For examining the β-cell and islet 
area, the area of the islets were traced manually and analyzed with Win ROOF software 
(Mitani Co., Fukui, Japan). More than 20 islets per pancreas were analyzed for the 
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average calculation.  
 
Statistical analysis  
Statistical analysis was performed using SAS system Version 8.2 (SAS Institute 
Inc., Cary, NC, USA). All values were expressed as means and SD. Statistical 
significance between groups was analyzed by the Student’s t-test. 
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Results 
 
Phenotypic characterization of GPR40/FFAR1 KO mice  
To generate GPR40/FFAR1 KO mice, a segment of the gene encoding the 
GPR40/FFAR1 protein was targeted by homologous recombination (Figure 6A). 
Obtained targeted ES cells were identified by Southern blotting using probes that 
hybridize outside of and adjacent to the targeting construct arms (Figure 6B), and the 
targeted clone was further used for creation of GPR40/FFAR1 KO mice. The genotypes 
of the obtained mice were determined to be wild-type (WT), heterozygote (HE), and 
homozygote (KO) by PCR (Figure 6C). The lack of mouse GPR40/FFAR1 gene 
expression was confirmed by quantitative real-time PCR analyses using pancreas tissues 
(Figure 6D). The GPR40/FFAR1 KO mice appeared generally normal, reproduced 
successfully, and showed Mendelian inheritance characteristics.  
 
Effects of high fat diet feeding on glucose homeostasis in GPR40/FFAR1 KO mice  
I explored the function of GPR40/FFAR1 in vivo under high-fat-diet conditions. 
GPR40/FFAR1 WT and KO mice were exposed to a high fat diet (containing 60 kcal% 
fat) for 8-11 weeks from 8 weeks of age. When WT mice were exposed to high-fat diet, 
plasma glucose, insulin, leptin, and NEFA levels and body weight in the fed state were 
significantly increased in compared with low-fat diet group (Table1). There was no 
significant difference in body weight and plasma parameters in the fed state between 
WT and KO mice under high-fat-diet conditions (Table 1). To assess the glucose 
homeostasis in these mice more precisely, an oral glucose tolerance test was performed 
after overnight fasting and areas under the curve (AUC) for glucose and insulin were 
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evaluated. Fasting plasma glucose, glucose levels in each time period of blood 
collection, and insulin levels at 15 min increased in both WT and KO mice given the 
high-fat diet (Figure 7B, D) as compared with those given low fat diet (Figure 7A, C), 
so the high-fat diet induced insulin resistance. But no significant differences in plasma 
glucose and insulin were observed between WT and KO mice on a high-fat diet (AUC 
of plasma glucose: 2261.8 ± 130.8 vs. 2424.9 ± 216.7 mmol/l x min, AUC of plasma 
insulin: 26521.6 ± 5709.0 vs. 27661.6± 15382.7 pmol/l x min for WT vs. KO mice, n=8). 
To evaluate the degree of insulin resistance, I calculated HOMA-IR. But no significant 
difference in HOMA-IR was observed between WT and KO mice on a low- and 
high-fat diet (Figure 7E). These data indicate that deletion of the GPR40/FFAR1 gene 
does not worsen high-fat-diet-induced glucose intolerance and insulin resistance.  
 
Metabolic characterizations of GPR40/FFAR1 KO mice harboring a diabetic 
genetic background  
The effects of the deletion of GPR40/FFAR1 were examined in genetically 
diabetic mice. Mice harboring KK background (50-52), were selected as mates, and the 
resultant mice containing almost 50% KK background (WT x KK and KO x KK) were 
used for further experiments. WT x KK mice showed the phenotype of apparent obesity 
and glucose intolerance almost similar to original KK mice, whereas KO x KK mice did 
not show significant differences in body weight, plasma glucose, or insulin levels in the 
fed state compared with WT x KK mice (Figure 8A-C). The oral glucose tolerance test 
revealed that glucose tolerance and insulin secretion in response to glucose remained 
identical in WT x KK and KO x KK mice (Figure 8D, E). To evaluate the degree of 
insulin resistance, I calculated HOMA-IR. But no significant difference in HOMA-IR 
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was observed between WT x KK and KO x KK mice (Figure 8F). These data indicate 
that deletion of GPR40/FFAR1 gene does not affect the glucose intolerance and other 
phenotypes of insulin resistance induced by KK background. 
 
Islet structure and β-cell function in vitro  
I next examined whether GPR40/FFAR1 deletion affected islet morphology. At 
16 weeks of age, immunohistochemical analyses of pancreas sections with antibodies 
against insulin, glucagon, GLUT2, and proinsulin showed no apparent differences 
between WT and KO mice (Figure 9A). β-cell and islet areas of KO mice were almost 
the same as those of WT mice (Figure 9B). To further examine the effects of 
GPR40/FFAR1 deletion on islet function in vitro, isolated islets from WT and KO mice 
at 19 weeks of age were stimulated with glucose or glucose plus palmitate, and secreted 
insulin was measured. As shown in Figure 9C, insulin secretory responses to high 
glucose (16 mmol/l) alone were similar in WT and KO mice islets. Stimulation with 
high glucose plus palmitate (1 mmol/l), an endogenous ligand of GPR40/FFAR1, 
significantly increased insulin secretion in islets of WT mice, but the insulinotropic 
effects of palmitate were significantly attenuated in the islets derived from KO mice 
(Figure 9D). On the other hand, insulin content was not different between WT and KO 
mice pancreas (Figure 9E). 
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Discussion 
 
  The objectives of this study were to examine whether loss of function of 
GPR40/FFAR1 exacerbates diabetes or not. I generated a strain of GPR40/FFAR1 
knockout mice and examined their phenotypes in vitro and in vivo. I found that 
GPR40/FFAR1 KO mice showed similar insulin resistance and the related harmful 
phenotypes induced by a high-fat diet and by transfer into a diabetic background 
compared to WT mice. That is; GPR40/FFAR1 KO mice on a high-fat diet became 
obese, developed glucose intolerance and insulin resistance at similar level as control 
mice; GPR40/FFAR1 KO mice harboring KK background also exhibited obesity, 
glucose intolerance, and insulin resistance at almost similar level as control KK 
background mice. These findings indicate that GPR40/FFAR1 does not contribute to 
worsen impaired glucose homeostasis under a high-fat diet and the KK genetic 
background. I observed that the insulinotropic effects of palmitate were selectively 
reduced in islets of the GPR40/FFAR1 KO mice, while the response to glucose was 
maintained. The results of my experiments using islets isolated from GPR40/FFAR1 KO 
mice are consistent with my in vivo results during the oral glucose tolerance test, and 
this is consistent with the results obtained by Latour et al (47). Meanwhile, insulin 
secretion after glucose load was not reduced in GPR40/FFAR1 KO mice, during glucose 
tolerance test. In addition, the plasma insulin levels were not significantly different 
between low fat diet and high fat diet condition. Regarding this discrepancy between ex 
vivo and in vivo, plasma insulin level is known to be affected by several things such as 
extrapancreatic factors (55) and intracellular metabolism of fatty acids (56). Although 
further studies are needed, I speculate that extrapancreatic factors and/or non- 
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GPR40/FFAR1 mediated action by fatty acids may affect plasma insulin in vivo. 
Furthermore, I observed no difference in islet structure and total insulin content between 
GPR40/FFAR1 KO and WT mice pancreas. These results suggest that GPR40/FFAR1 
plays a selective role in regulating insulin secretory process triggered by FFAs. 
Although several studies have shown the consistent results regarding the role of 
GPR40/FFAR1 in FFA-induced insulin secretion, the involvement in FFA-induced 
lipotoxicity in β-cells remains undetermined. While GPR40/FFAR1 has been proposed 
as a possible lipotoxicity mediator using a gene-engineered mouse (45), a number of 
experimental observations could not reproduce the results (40, 41, 46-49). This study 
also shows that there is no apparent difference between WT and KO mice in 
glucose-stimulated insulin secretion in islets ex vivo. Taken together, these results 
suggest that GPR40/FFAR1 would not play an significant role in mediating lipotoxicity. 
Although further studies are needed more in vivo experiments, this is consistent with 
reports using selective and potent small-molecule GPR40 agonists (37, 41). In addition, 
this immunohistochemical analyses showed that deletion of GPR40/FFAR1 did not alter 
the β-cell architecture, suggesting that GPR40/FFAR1 does not have a direct role in islet 
function and development.  
The correlation of the GPR40/FFAR1 gene and insulin secretion has been 
poorly studied in human subjects (30). It is reported that the genotype and allele 
frequencies of Arg211His polymorphism did not differ between type 2 diabetic patients 
and healthy subjects in Danish Caucasians (57). On the other hand, in healthy Japanese 
men, Arg211His polymorphism might contribute to the variation of insulin secretory 
capacity, which might link β-cell dysfunction and type2 diabetes (58). This discrepancy 
in the relationship between the Arg211His polymorphism of the GPR40/FFAR1 gene 
30 
 
and insulin secretory action might arise from different genetic backgrounds in nation or 
race. Furthermore, a newly identified GPR40/FFAR1 variant, Gly180Ser, is associated 
with reduced β-cell ability to adequately sense lipids as an insulin secretory stimulus, 
due to impaired increase in intracellular Ca2+ concentration (59). Although further 
studies will be needed, these findings may suggest that functional modulation of 
GPR40/FFAR1 gene, not GPR40/FFAR1 null mutation, affects insulin secretion and/or 
metabolic regulation. 
In conclusion, these data obtained from knockout mice suggest that 
GPR40/FFAR1 is selectively involved in fatty-acid-augmented insulin secretion, and 
does not contribute to development of glucose intolerance and insulin resistance under 
diabetogenic condition such as a high-fat diet and transfer of KK background. These 
findings indicate that loss of GPR40/FFAR1 function does not play an important role in 
inducing or exacerbating diabetes. 
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Tables and Figures 
 
Table 1. Metabolic parameters in GPR40/FFAR1 WT and KO mice fed on low-fat 
diet and high-fat diet for 8 weeks 
The GPR40/FFAR1 WT and KO mice were fed a low-fat diet containing 10 kcal% fat or 
a high-fat diet containing 60 kcal% fat diet for 8 weeks from 8 weeks of age. All 
parameters were measured in the fed state at 16 weeks of age. All values are means ± 
SD. n = 8 per genotype. 
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 Low-fat diet High-fat diet 
 WT KO WT KO 
Body weight (g) 28.9 ± 1.1 28.3 ± 3.2 36.8 ± 3.1 35.8 ± 3.4 
Calorie intake (kcal/day) 10.0 ± 1.0 11.5 ± 1.4 12.9 ± 1.3 14.0 ± 1.9 
Plasma glucose (mmol/l) 9.8 ± 1.0 9.9 ± 1.7 11.8 ± 1.3 11.7 ± 1.2 
Plasma insulin (pmol/l)  261.2 ± 101.3  105.7 ± 59.3  415.3 ± 160.0  412.5 ± 243.4 
Plasma leptin (ng/ml)  15.11 ± 8.11  11.84 ± 7.75  95.87 ± 25.03  68.33 ± 28.53 
Plasma NEFA (mmol/l)  0.33 ± 0.12  0.44 ± 0.21  0.65 ± 0.15  0.63 ± 0.07 
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Figure 6. Generation and characterization of GPR40/FFAR1 KO mice.  
(A) Structure of the targeting vector. (B) Southern blotting of ES cell clones. Shown are 
DNA samples from the targeted clones digested by SacI and probed with a 5’ probe, and 
by EcoRI and probed with a 3’ probe, respectively. WT: original ES cell, TA: targeted 
ES cell. (C) Representative PCR genotyping of DNA samples from tail clips of 
wild-type (WT), heterozygote (HE), and knock-out (KO) mice.WT:4, 6, 8, HE:1, 7, 9, 
10, 11, KO:2, 3, 5. (D) Expression of GPR40/FFAR1 mRNA in pancreas of WT, HE, 
and KO mice by quantitative real-time PCR analyses. mRNA levels of Actin were used 
as an internal control. All values are means ± SD. 
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Figure 7. Effects of high-fat diet on glucose homeostasis in GPR40/FFAR1 WT and 
KO mice.  
The WT (open circle) and KO(closed circle) mice were fed on low-fat (10 kcal%) diet 
and high-fat (60 kcal%) diet from 8 weeks of age; oral glucose tolerance test was 
performed at 19 weeks of age. Glucose was administered orally at 1 g/kg body weight. 
Plasma glucose and plasma insulin in low-fat diet (A, C) and high-fat diet (B, D) were 
measured and used to calculate HOMA-IR (E). All values are means ± SD. n = 8 per 
genotype. 
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Figure 8. Metabolic characterizations of GPR40/FFAR1 WT(open circles) and 
KO(closed circles)  mice harboring diabetic KK background on regular diet.  
Body weight (A), plasma glucose (B), and plasma insulin (C) at 18 weeks of age on 
regular diet. Oral glucose tolerance test for WT mice and KO mice harboring KK 
background. Glucose was administered orally at 1 g/kg body weight. Plasma glucose 
(D) and plasma insulin (E) at 24 weeks of age on regular diet were measured and used 
to calculate HOMA-IR (F). WT x KK (open circle) and KO x KK (closed circle) mean 
WT and KO mice containing almost 50% KK background, respectively. All values are 
means ± SD. n = 8 per genotype. 
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Figure 9. Islet structure and β-cell function of GPR40/FFAR1 WT and KO mice.  
(A) Islet morphology of WT and KO mice at 16 weeks of age fed with a regular diet. 
The sections were stained with anti-insulin, anti-glucagon, anti-GLUT2, and 
anti-proinsulin antibodies respectively. (B) β-cell and islet area was measured as the 
stained area for anti-insulin antibody. (C, D) Glucose and palmitate stimulated insulin 
secretion in isolated islets from WT (white bar) and KO (black bar) mice. Islets were 
isolated from WT and KO mice fed with a regular diet at 19 weeks. Five islets with 
similar sizes from each group (four batches in each group) were used. (E) Pancreatic 
insulin content. Pancreas was isolated from WT and KO mice fed with a regular diet at 
28 weeks and extracted by the acid-ethanol method. All values are means ± SD. * 
p≤0.05 vs. WT mice by Student’s t-test.    
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Chapter 2 
Overexpression of GPR40/FFAR1 in Pancreatic β-Cells Augments 
Glucose Stimulated Insulin Secretion and Improves Glucose Tolerance 
in Normal and Diabetic Mice 
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Abstract 
 
Backgrounds: GPR40/FFAR1 is a G protein-coupled receptor regulating free fatty 
acid-induced insulin secretion. I have generated transgenic mice overexpressing the 
human GPR40/FFAR1 gene (hGPR40/FFAR1-Tg) under control of the mouse insulin II 
promoter and have used them to examine the role of GPR40/FFAR1 in the regulation of 
insulin secretion and glucose homeostasis. 
Methods: Normal (C57BL/6J) and diabetic (KK) mice overexpressing the human 
GPR40/FFAR1 gene under control of the insulin II promoter were generated, and their 
glucose metabolism and islet function were analyzed.  
Results: In comparison with nontransgenic littermates, hGPR40/FFAR1-Tg mice 
exhibited improved oral glucose tolerance with an increase in insulin secretion. 
Although islet morphological analysis showed no obvious differences between 
hGPR40/FFAR1-Tg and nontransgenic (NonTg) mice, isolated islets from 
hGPR40/FFAR1-Tg mice enhanced insulin secretion in response to high glucose (16 
mM) than those from NonTg mice with unchanged low glucose (3 mM)-stimulated 
insulin secretion. In addition, hGPR40/FFAR1-Tg islets significantly increased insulin 
secretion against a naturally occurring agonist palmitate in the presence of 11 mM 
glucose. hGPR40/FFAR1-Tg mice were also found to be resistant to high fat 
diet-induced glucose intolerance, and hGPR40/FFAR1-Tg harboring KK mice showed 
augmented insulin secretion and improved oral glucose tolerance compared to 
nontransgenic littermates.  
Conclusions: These results suggest that GPR40/FFAR1 have a role in regulating 
glucose-stimulated insulin secretion and plasma glucose levels in vivo, and that 
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pharmacological activation of GPR40/FFAR1 may provide a novel insulin secretagogue 
beneficial for the treatment of type 2 diabetes. 
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Introduction 
 
Free fatty acids (FFAs) serve not only as nutrients but also as cell signaling 
mediators (60), and they are implicated in several metabolic disorders including 
diabetes. Elevated circulating FFAs cause insulin resistance and impair glucose 
metabolism in the liver, the muscle, the adipose tissue, and the pancreatic β-cells (61). 
In pancreatic β-cells, prolonged exposure to elevated levels of fatty acids together with 
high levels of glucose impairs β-cell function (43, 44) and induces cell death (42). In 
contrast to the toxic effects that accompany with chronic exposure, in acute treatment 
FFAs play an essential role to amplify glucose stimulated insulin secretion (GSIS) (22, 
23).  
  GPR40/FFAR1 was identified as a receptor for medium- and long-chain FFAs 
and is preferentially expressed at high levels in rodent primary β-cells, β-cell lines 
(26-29), and human islets (30, 31). Several reports have shown that GPR40/FFAR1 is 
mainly coupled with Gαq/Gα11, which activates phosholipase C (PLC) resulting in the 
formation of inositol 1, 4, 5-triphosphate (IP3) and induction of calcium release from 
endoplasmic reticulum (29, 32-34). In fact, FFAs increase intracellular calcium 
concentration via GPR40/FFAR1 and lead to glucose dependent augmentation of insulin 
secretion (26-29, 33, 36).  
Although several studies have shown the important role of GPR40/FFAR1 in 
FFA-induced insulin secretion, the involvement of GPR40/FFAR1 in FFA-induced 
lipotoxicity in β-cells remains controversial. Steneberg et al. reported that 
overexpression of GPR40/FFAR1 in β-cells under the control of the Ipf1/Pdx1 promoter 
lead to β-cell dysfunction, hypoinsulinemia and diabetes (45). In contrast, studies of 
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GPR40/FFAR1 knockout mice showed that GPR40/FFAR1 did not play a role in the 
mechanism by which chronic treatment with fatty acids impaired insulin secretion (37, 
47). Furthermore, both acute and chronic treatment with small molecule agonists of 
GPR40/FFAR1 caused enhancement of glucose stimulated insulin secretion and 
improved glucose tolerance (37-39). Together, these reports suggested that 
GPR40/FFAR1 agonist is not harmful to β-cells, but in fact may prove beneficial for the 
treatment of type 2 diabetes.  
  To clarify the function of GPR40/FFAR1 in pancreatic β-cells more extensively, 
I generated transgenic mice overexpressing the human GPR40/FFAR1 gene under 
control of the insulin II promoter (hGPR40/FFAR1-Tg) and examined the role of 
GPR40/FFAR1 in the regulation of insulin secretion and glucose homeostasis. I found 
that hGPR40/FFAR1-Tg mice displayed improved glucose tolerance with augmented 
insulin secretion both in regular and high fat diet feeding conditions. Moreover, even 
when the insulin resistance was reinforced in diabetic KK mice, overexpression of 
hGPR40 in this background also improved glucose tolerance with increasing insulin 
secretion. Thus, these findings indicated that GPR40/FFAR1 has a role in regulating 
glucose-stimulated insulin secretion and plasma glucose levels in vivo, and supported 
the concept that GPR40/FFAR1 agonists might be effective insulin secretagogues for the 
treatment of type 2 diabetes. 
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Materials and Methods 
 
Generation of hGPR40/FFAR1-Tg mice 
The transgene consisted of 0.7 kbp of mouse insulin II gene promoter, followed 
by 2.2 kbp of the human GPR40/FFAR1 cDNA including the 3’-noncoding region (8) 
and the complete 2.9 kbp fragment was purified and microinjected into the fertilized 
eggs of C57BL/6J mouse (CLEA Japan Inc., Tokyo, Japan) (62). The obtained 
transgenic mice were maintained by crossing with C57BL/6J mice, and the transgenic 
founder mice were identified by polymerase chain reaction (PCR) analyses of tail DNAs 
using the human GPR40/FFAR1 gene specific primers 
(5’-GGAGTGTGGTGCTTAATCCGCTGGT-3’ and 
5’-AGACTGCCTCCTCCTTCCCGTAAGTACAA-3’). When examining the 
hGPR40/FFAR1-Tg mice harboring KK hybrid background, hGPR40/FFAR1-Tg mice 
were crossed with mice harboring KK background and obtained mice containing almost 
50% of KK background (hGPR40/FFAR1-Tg x KK). The transgene was identified by 
PCR analyses of tail DNAs using the human GPR40/FFAR1 specific primers (described 
as above). Age and sex matched littermates were used as control mice throughout the 
study, and all experiments were conducted using male mice unless otherwise stated. The 
mice were fed with a regular diet CE-2 containing 11.5 kcal% fat (CLEA Japan Inc.), 
and were housed in colony cages and maintained on a 12-hr/12-hr light-dark cycle with 
free access to water and food. When examining the effects of high fat diet feeding, mice 
were fed with a high fat diet containing 60 kcal% fat (D12492, Research Diets Inc, New 
Brunswick, NJ, USA) from 8 weeks of age. Plasma glucose levels were automatically 
analyzed by DRI-CHEM (FujiFilm Medical, Tokyo, Japan) and plasma non-esterified 
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fatty acids (NEFA) were determined using Wako Test (Wako Pure Chemical Industries 
Ltd, Osaka, Japan). Plasma insulin levels were measured by enzyme-linked 
immunosorbent assay (ELISA) (Morinaga Institute of Biological Science Inc., Tokyo, 
Japan). All procedures were conducted according to the Experimental Animal Care Use 
Committee of Takeda Pharmaceutical Company Ltd.  
 
Oral glucose tolerance test  
As described in Chapter 1, mice were orally administered with glucose at a 
dose of 1 g/kg body weight in the case of C57BL/6J or 2 g/kg body weight in the case 
of KK hybrid mice after an overnight fast. In the case of C57BL/6J mice, blood samples 
were obtained at time 0 (just before glucose load), 7.5, 15, 30, 60, and 120 min after 
glucose administration, followed by plasma preparation by centrifugation. In the case of 
KK hybrid mice, blood samples were collected at 10 min instead of 7.5 and 15 min. 
Plasma glucose and insulin levels were measured as described above.  
 
Insulin tolerance test  
Insulin was injected intraperitoneally at 0.5 units/kg body weight (Novo 
Nordisk, Bagsværd, Denmark) after an overnight fast. Blood samples were obtained at 
time 0 (just before insulin injection), 30, 60, and 120 min after insulin injection, 
followed by plasma preparation by centrifugation. Plasma glucose level was measured 
as described above. 
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Preparation of islets  
As described in Chapter 1, Islets were isolated from the pancreas by 
collagenase digestion (54). The solution of 183 units/mg/kg collagenase (Wako Pure 
Chemical Industries Ltd.) dissolved in Hanks' Balanced Salt Solutions (HBSS; 
Invitrogen, Carlsbad, CA, USA) containing 10 μg/ml DNase I (Roche Diagnostics, 
Indianapolis, IN, USA) and 0.2% bovine serum albumin (BSA; Wako Pure Chemical 
Industries Ltd.), was injected into the common bile duct. The pancreas was removed and 
incubated at 37°C for 20 min, washed 3 times with HBSS, and islets were 
hand-collected under a microscope. Freshly purified islets were used for gene 
expression experiments. For insulin secretion experiments, purified islets were used 
after overnight culture in RPMI 1640 medium containing 5.5 mM glucose, 10% fetal 
bovine serum (FBS) in a humidified atmosphere containing 5% CO2/95% air at 37°C. 
 
RNA extraction and gene expression analysis  
Total RNA was extracted from the isolated islets, the liver, the subcutaneous 
adipose tissue, the muscle, the brain, and the kidney using RNeasy Mini kit (QIAGEN, 
Tokyo, Japan), and reverse transcription was performed with random hexamer and 
reverse transcriptase (GE Healthcare UK Ltd., Chalfont St. Giles, UK). Quantitative 
real-time PCR analyses were performed using a Prism 7700 sequence detector (Applied 
Biosystems, Foster City, CA, USA), following the manufacturer’s instructions. The 
primers were as follows: 5'-GCCCGCTTCAGCCTCTCT-3' and 
5'-GAGGCAGCCCACGTAGCA-3' with 
5'-FAM-TCTGCCCTTGGCCATCACAGCCT-TAMRA-3' TaqMan probe for the 
human GPR40/FFAR1 gene, 5'-GGGCCTCTGGAAAGGGACT-3' and 
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5'-ACCAGCTCAGCACAGTTGACA-3' with 5'- 
FAM-TCCCAATGTTGCCCGTAATGCCA-TAMRA-3' TaqMan probe for the mouse 
UCP2 gene, and 5'-CGTGAAAAGATGACCCAGATCA-3' and 
5'-CACAGCCTGGATGGCTACGT-3' with 5'- 
FAM-TGAGACCTTCAACACCCCAGCCATG-TAMRA-3' TaqMan probe for the 
mouse actin gene. The mouse GPR40/FFAR1, insulin II, GLUT2, and glucokinase genes 
were quantified by Gene Expression Assays (Mm00809442_m1, Mm00731595_gH, 
Mm00446224_m1, and Mm00439129_m1, respectively, Applied Biosystems, Foster 
City, CA, USA)   
 
Insulin secretion assay  
Groups of five islets was preincubated in Krebs-Ringer biocarbonate buffer 
(KRBH) containing 0.2% BSA and 1 mM glucose for 30 min at 37°C, and then 
incubated for another 1 hr in KRBH containing glucose. When examining the effect of 
the fatty acids, sodium palmitate (CHEM SERVICE, Inc, West Chester, PA, USA) was 
conjugated with FFA-free BSA (SIGMA ALDRICH Inc., St.Louis, MO, USA) at final 
palmitate and BSA concentrations of 1 mM and 0.2%, respectively. The conjugated 
palmitate was added to KRBH containing 11 mM glucose, and incubated for 1hr. At the 
end of the incubation period, the amount of insulin in the culture supernatant was 
determined with ELISA as described above. Residual islets were sonicated and used to 
determine the DNA content (Quant-iTTM Picogreen dsDNA Assay Kit, Invitrogen, 
Carlsbad, CA, USA). 
 
 
51 
 
Immunohistochemistry of pancreas  
Formalin-fixed, paraffin-embedded tissue sections (thickness of 4 μm) of the 
pancreas were immunostained using the avidin-biotin detection system (Ventana 
Medical Systems, Tucson, AZ, USA) and M.O.M. immunodettection kit (VECTOR 
Laboratories, Inc., Burlingame, CA, USA), according to the manufacturer’s instructions. 
Anti-insulin antibody (1:200, MP Biomedicals Inc, Morgan Irvine, CA, USA), 
anti-glucagon antibody (1:2, ZYMED, South San Francisco, CA, USA), anti-GLUT2 
antibody (1:200, CHEMICON International Inc, Temecula, CA, USA), and 
anti-proinsulin antibody (ready-to-use, Lab Vision, Fremont, CA, USA) were used as 
primary antibodies. When examining the β-cells area, the area of the islets were traced 
manually and analyzed with Win ROOF software (Mitani Co., Fukui, Japan). More than 
20 islets per pancreas were analyzed for the average calculation.  
 
Statistical analysis  
Statistical analysis was performed using SAS system Version 8.2 (SAS institute 
Inc., Cary, NC, USA). All values were expressed as means and S.E. Statistical 
significance between groups was analyzed by the Student’s t-test. 
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Results 
 
Improved glucose tolerance in human GPR40/FFAR1 transgenic mouse harboring 
normal background  
To investigate the role of the GPR40/FFAR1 gene in pancreatic β-cells, I 
generated mice overexpressing human GPR40/FFAR1 cDNA under control of the mouse 
insulin II promoter (Figure 10A). Two transgene expressing lines, named 
hGPR40/FFAR1-Tg 47M and 23F, were established by microinjection of the construct 
into C57BL/6J oocytes. High expression levels of human GPR40/FFAR1 gene were 
confirmed in isolated islets from both male transgenic lines at 9 weeks of age (Figure 
10B). The expression levels of the human GPR40/FFAR1 mRNA were more than 10 
times higher than those of endogenous mouse GPR40/FFAR1 gene in both of the two 
lines. The 47M lines showed 2.8 times higher expression levels of the human 
GPR40/FFAR1 mRNA in islets than the 23F lines. Expression of human GPR40/FFAR1 
gene was extremely low in the other tissues, but slight expression was found in the 
kidney in 47M line, but the expression level in kidney in 23F line is extremely low. 
These transgenic lines appeared generally normal, reproduced successfully, and showed 
Mendelian inheritance characteristics.  
  Both of hGPR40/FFAR1-Tg lines (47M and 23F) did not show significant 
differences in body weight, plasma glucose, plasma insulin, and NEFA levels compared 
to nontransgenic mice (NonTg) in the fed state on a regular diet (Table 2). However, 
fasting plasma glucose levels were lower in hGPR40/FFAR1-Tg than in NonTg mice. To 
assess the glucose homeostasis in these mice more precisely, oral glucose tolerance test              
and insulin tolerance test were performed and area under the curve (AUC) for glucose 
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and insulin were calculated. AUC0-120min of plasma glucose after glucose load in both 
lines of hGPR40/FFAR1-Tg mice were significantly lower than those in NonTg mice 
(Figure 11A, B, E). In parallel with improvement of glucose tolerance, insulin responses 
to glucose at the early-phase were higher in both hGPR40/FFAR1-Tg than NonTg mice 
(Figure 11C, D), and AUC0-30min of plasma insulin was significantly increased in both 
line of hGPR40/FFAR1-Tg mice compared with NonTg mice (Figure 11F). Whole body 
insulin sensitivity was assessed by the insulin tolerance test, and no apparent differences 
were observed between hGPR40/FFAR1-Tg and NonTg mice (Figure 11G, H).  
 
Islet structure and β-cell function in vitro 
I next examined whether the human GPR40/FFAR1 overexpression affects islet 
structure. Immunohistochemical analysis of pancreas sections with antibodies against 
insulin, glucagon, GLUT2, and proinsulin showed no apparent differences between 
hGPR40/FFAR1-Tg (47M and 23F) and NonTg mice at 16 weeks of age (Figure 12A). 
β-cell area of 47M and 23F lines were almost the same as that of NonTg mice (Figure 
12B). To further examine the effects of the human GPR40/FFAR1 overexpression on 
islet function, isolated islets from hGPR40/FFAR1-Tg (47M, 23F) mice and NonTg 
mice at 9 weeks of age were stimulated with glucose or glucose plus palmitate in vitro, 
and secreted insulin was measured. Basal insulin secretion at low glucose concentration 
(3 mM) was similar between hGPR40/FFAR1-Tg and NonTg islets, but isolated islets 
from hGPR40/FFAR1-Tg mice showed enhanced insulin secretion in response to high 
glucose (16 mM) than those from NonTg mice (Figure 12C). Similar results were 
obtained when using islets isolated from 23F line (Figure 12D). Stimulation with 
palmitate significantly increased insulin secretion in islets of hGPR40/FFAR1-Tg mice 
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than those of NonTg mice at 11 mM glucose, indicating that the expressed human 
GPR40/FFAR1 might be functional in β-cells of hGPR40/FFAR1-Tg mice (Figure 12E). 
According to these results, it was speculated that the quantity of insulin secretion was 
more enhanced than that of insulin synthesis in hGPR40/FFAR1-Tg mice islets. 
 
Effects of high fat diet feeding on glucose homeostasis in hGPR40/FFAR1-Tg mice 
 Since GPR40/FFAR1 is the receptor for medium- and long-chain FFAs 
(26-28) and a previous report suggested the involvement of GPR40/FFAR1 in 
FFA-induced lipotoxicity in β-cell (45), I next explored the function of GPR40/FFAR1 
in vivo under high fat diet (HFD) conditions. hGPR40/FFAR1-Tg mice (47M) were 
exposed to HFD for 9-12 weeks from 8 weeks of age. When NonTg mice were exposed 
to HFD, body weight, plasma glucose, insulin, and NEFA levels in the fed state were 
increased in compared with regular diet (Table 2). There were no obvious differences in 
body weight and plasma parameters in the fed state between hGPR40/FFAR1-Tg and 
NonTg mice, but fasting plasma glucose levels were significantly decreased in 
hGPR40/FFAR1-Tg mice in HFD condition, compared with those observed in regular 
diet condition (Table 2). Oral glucose tolerance test showed improved glucose tolerance 
(Figure 13A, C) and augmented insulin secretion in response to glucose (Figure 13B, D) 
in hGPR40/FFAR1-Tg mice compared to NonTg mice. No apparent difference in insulin 
sensitivity or in the epididymal adipose tissue weight was observed between 
hGPR40/FFAR1-Tg and NonTg mice (Figure 13E, F). These results indicated that 
improved glucose tolerance with increased insulin secretion in hGPR40/FFAR1-Tg mice 
was maintained under conditions of HFD-induced insulin resistance.  
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Improved glucose tolerance in hGPR40/FFAR1-Tg mice harboring diabetic genetic 
background 
  The effects of overexpression of GPR40/FFAR1 in pancreatic β-cells were 
examined in genetically diabetic mice. Mice harboring KK background, exhibiting 
obese, glucose intolerance and insulin resistance (51), were selected as mates, and male 
hGPR40/FFAR1-Tg (47M) and Non-Tg mice were crossed to female harboring KK 
background mice. Although the obtained mice had a hybrid genetic background 
harboring approximate 50% of KK and C57BL/6J mice, the obtained nontransgenic 
mice (NonTg x KK mice) showed heavier body weight and higher plasma insulin levels 
than NonTg C57BL/6J mice at 16 weeks of age fed with regular chow (body weight 
28.8 ± 0.4 v.s. 38.9 ± 0.57 g, plasma insulin 1.54 ± 0.30 v.s. 5.79 ± 1.83 ng/ml, NonTg 
C57BL/6J v.s. NonTg x KK, respectively; n=7-10). Human GPR40/FFAR1 gene 
expression level in islets of hGPR40/FFAR1-Tg x KK mice was more than 10 times 
higher than that of the mouse gene (Figure 14A). The hGPR40/FFAR1-Tg x KK mice 
did not show significant differences in body weight, plasma glucose, and insulin levels 
from NonTg x KK mice at 10 weeks of age (Table 3). Oral glucose tolerance test at 12 
weeks of age revealed improved glucose tolerance and increased insulin secretion in 
hGPR40/FFAR1-Tg x KK mice compared to NonTg x KK mice (Figure 14B-E). We 
next examined the insulin secretion in response to glucose in vitro using islets from 
hGPR40/FFAR1-Tg x KK and NonTg x KK mice at 12 weeks of age. Although basal 
insulin secretion from islets in response to low glucose concentration (3 mM) was 
closely similar between hGPR40/FFAR1-Tg x KK and NonTg x KK mice, insulin 
secretion against high glucose stimulation (16 mM) was 3.5-fold higher in 
hGPR40/FFAR1-Tg x KK islets compared to NonTg x KK islets (Figure 14F). 
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Stimulation with 1 mM palmitate enhanced insulin secretion in islets of 
hGPR40/FFAR1-Tg x KK mice more than those of NonTg x KK mice at 11 mM glucose 
(Figure 14G). 
 
Gene expression of factors regulating insulin secretion in islets isolated from 
hGPR40/FFAR1-Tg mice 
  To investigate the molecular mechanisms for enhanced insulin secretion in 
response to high glucose stimulation in hGPR40/FFAR1-Tg mice in vitro and in vivo, 
gene expression levels of factors regulating insulin secretion were compared between 
islets from hGPR40/FFAR1-Tg (47M) and NonTg mice after HFD feeding for 9 weeks. 
The gene expression levels of insulin II, GLUT2, and glucokinase were found to be 
almost the same between hGPR40/FFAR1-Tg and NonTg mice islets (Figure 15). I also 
examined the gene expression levels of UCP2, which negatively regulates insulin 
secretion in β-cells (26-28), and the expression level of UCP2 did not change between 
hGPR40/FFAR1-Tg and NonTg mice (Figure 15). 
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Discussion 
 
In this study, I have shown that overexpression of the human GPR40/FFAR1 
gene by using insulin II promoter resulted in improved glucose tolerance with 
augmented insulin secretion, and the phenotype of hGPR40/FFAR1-Tg mice was not 
altered by HFD feeding or by gene transfer into a diabetic background. I found the 
extremely high expression in pancreatic islets in two independent lines, but slight 
expression was detected in the kidney in 47M line. Both 47M and 23F h 
GPR40/FFAR1-Tg mice showed the same phenotype, and therefore it is unlikely that the 
expression in kidney affects the phenotype of hGPR40/FFAR1-Tg mice. The 
hGPR40/FFAR1-Tg mice showed slightly lower plasma glucose levels than NonTg mice 
in fasted state but not in fed state. These results might reflect the differential activation 
of GPR40/FFAR1 between the fasted and the fed state, since natural ligands of 
GPR40/FFAR1 were FFAs (26-28), and FFA levels were significantly increased after an 
overnight fast in mice. In the fasted state, GPR40/FFAR1 may be more strongly 
activated than in the fed state, resulting in enhanced insulin secretion and reduced 
plasma glucose levels. In fact, insulin levels were tended to increase in 
hGPR40/FFAR1-Tg mice than NonTg mice in the fasted state.  
Isolated islets from hGPR40/FFAR1-Tg mice secreted insulin significantly 
when stimulated with palmitate and glucose per se. Although I do not have direct 
evidence for GPR40/FFAR1 protein expression level, it was proposed that 
GPR40/FFAR1 activation by fatty acids stimulates the Gαq-PLC signaling pathway, 
involving activation of PLC and production of IP3, which leads to release of calcium 
from the endoplasmic reticulum (29, 32-34). Glucose and fatty acids could also 
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augment insulin secretion through pathways involving protein kinase C (PKC) (63, 64). 
The mechanism of enhanced GSIS observed in hGPR40/FFAR1-Tg mice islets remains 
unclear so far, so further studies will be needed to clarify the precise mechanism. 
Steneberg et al. reported that the GPR40/FFAR1 transgenic mice driven by the 
Ipf1/Pdx1 promoter leads to impaired β-cells function, hypoinsulinemia, and glucose 
intolerance (45), suggesting the involvement of GPR40/FFAR1 in FFA-induced toxicity 
in β-cells. In contrast, hGPR40/FFAR1-Tg mice did not develop diabetes even after 
HFD feeding for 8-12 weeks. The reason for the discrepancy remains unknown. 
Although I may need further examination, the possible explanations are below. One is 
the different promoters used for the production of transgenic mice. The temporal pattern 
of expression of Ipf1/Pdx1 during development was different from that of insulin II (65). 
Transgene of GPR40/FFAR1 regulated by Ipf1/Pdx1 promoter might be expressed in 
pancreatic progenitors in the early embryonic stage and these expression patterns might 
influenced the phenotype. Second, it may be caused by the difference of genetic 
background of each transgenic mouse. Third, the difference of GPR40/FFAR1 gene 
levels between my transgenic mouse and Steneberg’s mouse would be possible. In 
addition, my preliminary results showed that the hGPR40/FFAR1-Tg mice fed with 
HFD for long term (more than 50 weeks) maintained improved glucose tolerance with 
increased insulin secretion, without changes in body weight and plasma parameters 
including plasma insulin levels. Therefore, from these results, it was suggested that 
activation of GPR40/FFAR1 function might not cause lipotoxicity. Latour et al. (47) and 
Tan et al. (37) demonstrated that islets from GPR40/FFAR1 knockout mice were as 
sensitive to fatty acid inhibition of insulin secretion upon prolonged exposure as islets 
from wild-type animals, and they concluded that GPR40/FFAR1 does not play a role in 
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the mechanisms by which fatty acids chronically impair insulin secretion. Moreover, 
Kebede et al. reported that GPR40/FFAR1 knockout mice showed fasting 
hyperglycemia and were not protected from HFD-induced insulin resistance (48). 
Although further studies will be needed to clarify the relation between GPR40/FFAR1 
and lipotoxicity, these observations are consistent with my findings. Furthermore, small 
molecule agonists of GPR40/FFAR1 have been reported (37-39), and they could 
enhance glucose stimulated insulin secretion and improved glucose tolerance in both 
acutely and chronically. Results from these reports indicated that activation of 
GPR40/FFAR1 might be beneficial for glucose control in type 2 diabetes mellitus 
without lipotoxicity and the phenotypes of hGPR40/FFAR1-Tg mice strongly support 
this conclusion. 
Obesity commonly induces insulin resistance and causes an increase in the 
requirement of insulin secretion from the pancreas, and the enhancement of this 
phenomenon further exacerbates obesity and insulin resistance. The molecular 
mechanism of this phenomenon is unclear, but may be related to increased production 
and secretion of non-esterified fatty acids and metabolically harmful adipokines by 
insulin-resistant adipocytes during obesity (66-68). In these results, hGPR40/FFAR1-Tg 
mice fed on HFD did not show significant differences in body weight, adipose tissue 
weight, and plasma insulin level. Moreover, when insulin resistance was reinforced by 
crossing with KK background harboring mice, hGPR40/FFAR1-Tg x KK mice did not 
show significant differences in body weight and plasma insulin level from NonTg x KK 
mice. Therefore, activation of GPR40/FFAR1 may not cause sustained hyperinsulinemia 
but may enhance glucose-stimulated insulin secretion essentially in the prandial period. 
The M3 muscarinic acetylcholine receptor subtype is coupled with Gαq in 
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pancreatic β-cells (69, 70). It has been reported that overexpressed M3 muscarinic 
receptors in pancreatic β-cells showed almost the same phenotype with the 
hGPR40/FFAR1-Tg mice (71), and the potentiation of Gαq signaling in pancreatic 
β-cells may maintain proper insulin release and glucose homeostasis in vivo. 
In conclusion, these results demonstrate that GPR40/FFAR1 may play an 
important role to regulate glucose-stimulated insulin secretion and glucose homeostasis. 
My observation indicates that GPR40/FFAR1 might be concerned with overt increase in 
insulin secretion in the presence of elevated glucose such as during the postprandial 
period, and that specific agonists may be useful as novel insulin secretagogues with low 
risk of hypoglycemia. 
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Table 2. Metabolic parameters in hGPR40/FFAR1-Tg (47M, 23F) mice fed on 
regular diet and high fat diet 
All parameters were measured in the fed and fasted state at 16 weeks of age on regular 
diet. The hGPR40/FFAR1-Tg (47M) and NonTg mice were fed on high fat diet 
containing 60 kcal% fat for 12 weeks. All parameters were measured in the fed and 
fasted state at 20 weeks of age. All values are means ± S.E. n = 7-10 per genotype. 
**p≤0.01 by Student’s t-test v.s. NonTg mice. 
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Body weight 
(g) 
Plasma glucose  
(mg/dl)         
Plasma insulin 
(ng/ml) 
Plasma NEFA 
(mEq/l) 
Regular diet 
 
 
 
 
 
 
 
Fed 
 
 
 
NonTg 28.8 ± 0.4 170.0 ± 4.1 1.54 ± 0.30 0.33 ± 0.08 
Tg (47M) 27.5 ± 0.6 153.6 ± 6.2 1.61 ± 0.43 0.24 ± 0.06 
NonTg 28.7 ± 0.4 187.6 ± 9.8 1.43 ± 0.38 0.37 ± 0.08 
Tg (23F) 28.1 ± 0.3 161.4 ± 8.1 1.46 ± 0.38 0.41 ±0.06 
Fasted 
 
 
NonTg 24.3 ± 0.4 106.0 ± 4.8  0.19 ± 0.04 1.35 ± 0.06 
Tg (47M) 22.9 ± 0.6 84.5 ± 4.4** 0.23 ± 0.05 1.00 ± 0.07  
NonTg 24.0 ± 0.3 117.7 ± 5.0 0.21 ± 0.03 1.07 ± 0.07 
Tg (23F) 23.6 ± 0.3 89.9 ± 5.2** 0.24 ± 0.05 0.98 ± 0.07 
High fat diet 
 
 
Fed 
 
NonTg 49.9 ± 0.7 215.6 ± 8.1 18.87 ± 3.52 0.52 ± 0.04 
Tg (47M) 49.6 ± 1.0 212.8 ± 9.9 16.17 ± 2.95 0.49 ± 0.03 
Fasted NonTg 46.0 ± 0.6 173.8 ± 5.6 2.88 ± 0.31 0.80 ± 0.04 
Tg (47M) 45.4 ± 0.9 133.3 ± 4.5** 3.07 ± 0.39 0.80 ± 0.04 
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Table 3. Metabolic parameters in hGPR40/FFAR1-Tg mice crossed with KK mice 
fed on regular diet 
The hGPR40/FFAR1-Tg (47M) mice harboring C57BL/6J and KK background were 
used for analyses. All parameters were measured in fed state at 10 weeks of age. All 
values are means ± S.E. n = 8-10 per genotype. 
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Regular diet 
Crossed with KK 
Body weight 
(g) 
Plasma glucose 
(mg/dl) 
Plasma insulin  
(ng/ml) 
NonTg 33.8 ± 0.7 200.1 ± 5.8 2.18 ± 0.58 
Tg 33.3 ± 0.5 208.5 ± 5.9 3.65 ± 0.76 
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Figure 10. Generation and characterization of hGPR40/FFAR1-Tg mice. 
(A) A DNA construct for microinjection to generate transgenic mice for the mouse 
insulin II promoter and human GPR40/FFAR1 gene. The box denotes the coding region 
of human GPR40/FFAR1 cDNA. B: Human and mouse GPR40/FFAR1 mRNA levels 
from hGPR40/FFAR1-Tg (47M, 23F, n = 3) and NonTg mice (n = 3) by quantitative 
real-time PCR analyses. mRNA levels of Actin were used as an internal control. Is: islet, 
L: liver, A: subcutaneous adipose tissue, M: muscle, B: brain, K: kidney.  
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Figure 11. Improved glucose tolerance in human GPR40/FFAR1 transgenic mice 
harboring C57BL/6J background. 
Oral glucose tolerance test in NonTg (open circle) and hGPR40/FFAR1-Tg (closed 
circle) on regular diet. Glucose was administered orally at 1 g/kg body weight. Plasma 
glucose and plasma insulin in 47M line at 16 weeks of age (A, C, n = 8) and in 23F line 
at 15 weeks of age (B, D, n = 10), respectively. Data in (E) represents the area under the 
curve of plasma glucose (0-120 min) shown in (A, B) and data in (F) represents the area 
under the curve of plasma insulin (0-30 min) shown in (C, D). (G, H) Insulin tolerance 
test for NonTg and hGPR40/FFAR1-Tg mice. Insulin was injected intraperitonealy at 
0.5 units/kg. Plasma glucose on regular diet at 14-15 weeks of 47M (G, n = 13-15) and 
23F (H, n = 5-7), respectively. All values are means ± S.E. **p≤0.01, *p≤0.05 v.s. 
NonTg mice by Student’s t-test.  
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Figure 12. Islet structure and β-cell function of hGPR40/FFAR1-Tg mice and 
NonTg mice. 
(A) Islet morphology of hGPR40/FFAR1-Tg (47M, 23F) and NonTg mice at 16 weeks 
of age. The sections were stained with anti-insulin, anti-glucagon, anti-GLUT2, and 
anti-proinsulin antibodies respectively. (B) β-cell area was measured as the stained area 
for anti-insulin antibody. (C, D) Glucose stimulated insulin secretion in isolated islets 
from hGPR40/FFAR1-Tg and NonTg mice. (E) Palmitate stimulated insulin secretion in 
isolated islets from hGPR40/FFAR1-Tg (47M) mice and NonTg mice. Islets were 
isolated from hGPR40/FFAR1-Tg and NonTg mice fed on regular diet at 9 weeks. Five 
islets with similar sizes from each group (four batches in each group) were used. All 
values are means ± S.E. **p≤0.01, *p≤0.05 v.s. NonTg mice by Student’s t-test.  
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Figure 13. Effects of high fat diet feeding on glucose homeostasis in 
hGPR40/FFAR1-Tg mice. 
The hGPR40/FFAR1-Tg (47M) and NonTg mice were fed on 60 kcal% fat diet from 8 
weeks of age. Oral glucose tolerance test for hGPR40/FFAR1-Tg mice and NonTg mice. 
Glucose was administered orally at 1 g/kg body weight. Plasma glucose (A) and plasma 
insulin (B) at 17 weeks of age, respectively. Data in (C) represents the area under the 
curve of plasma glucose (0-120 min) shown in (A) and data in (D) represents the area 
under the curve of plasma insulin (0-30 min) shown in (B). (E) Insulin tolerance test for 
NonTg and hGPR40/FFAR1-Tg mice. Insulin was injected intraperitonealy at 0.5 
units/kg. Plasma glucose on high fat diet at 20 weeks of age. (F) Epididymal adipose 
tissue weight at 20 weeks of age. All values are means ± S.E. (n = 10). **p≤0.01 v.s. 
NonTg mice by Student’s t-test.  
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Figure 14. Improved glucose tolerance in hGPR40/FFAR1-Tg mice harboring 
diabetic background of KK on regular diet. 
(A) Human and mouse GPR40/FFAR1 mRNA levels in islets from hGPR40/FFAR1-Tg 
x KK and NonTg x KK mice (n = 3) by quantitative real-time PCR analyses. mRNA 
levels of Actin were used as an internal control. (B-E) Oral glucose tolerance test for 
hGPR40/FFAR1-Tg mice and NonTg mice harboring hybrid background. Glucose was 
administered orally at 2 g/kg body weight. Plasma glucose (B) and plasma insulin (C) at 
12 weeks of age on regular diet. Data in (D) represents the area under the curve of 
plasma glucose (0-120 min) shown in (B) and data in (E) represents the area under the 
curve of plasma insulin (0-30 min) shown in (C). (F, G) Glucose and palmitate 
stimulated insulin secretion in isolated islets from hGPR40/FFAR1-Tg x KK and NonTg 
x KK mice. Islets were isolated from mice fed on regular diet at 12 weeks. Five islets 
with similar sizes from each group (four batches in each group) were used. All values 
are means ± S.E. (n = 8-10). **p≤0.01, *p≤0.05 v.s. NonTg mice by Student’s t-test.  
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Figure 15. Gene expression profiles in islets from hGPR40/FFAR1-Tg and NonTg 
mice. 
The hGPR40/FFAR1-Tg (47M) and NonTg mice were fed on 60 kcal% fat diet for 9 
weeks. At each group, the islets from more than three mice were collected, and mRNA 
levels of indicated genes were estimated by quantitative real-time PCR analyses at 
duplicate. mRNA levels of Actin were used as an internal control. Ratios in 
hGPR40/FFAR1-Tg mice were with respect to values in NonTg mice. All values are 
means ± S.E. (n = 3-4). Gck; glucokinase. 
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General Discussion 
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To clarify whether loss of function of GPR40/FFAR1 exacerbates diabetes or 
not, I have generated GPR40/FFAR1 knockout mice and examined their phenotypes in 
vitro and in vivo under high-fat-diet feeding in chapter 1. Moreover, to clarify the 
function of GPR40/FFAR1 in pancreatic β-cells more extensively, I generated transgenic 
mice overexpressing the human GPR40/FFAR1 gene under control of the insulin II 
promoter (hGPR40/FFAR1-Tg) and examined the role of GPR40/FFAR1 in the 
regulation of insulin secretion and glucose homeostasis in chapter 2. 
Type 2 diabetes mellitus is characterized by elevated plasma glucose levels 
arising from increased peripheral insulin resistance and impaired insulin secretion. 
GPR40/FFAR1 was identified as a receptor for medium- and long-chain FFAs and was 
preferentially expressed at high levels in pancreatic β-cells. GPR40/FFAR1 lead to 
glucose dependent augmentation of insulin secretion in vitro, and GPR40/FFAR1 
agonist may be the candidate of new drug for the treatment of type 2 diabetes and the 
mechanism of insulin secretion via GPR40/FFAR1 was clarified in vitro, whearas the 
function of GPR40/FFAR1 in vivo was not clarified yet. 
In the first chapter, GPR40/FFAR1 knockout mice (KO) mice were generated 
and evaluated their phenotypes. GPR40/FFAR1 KO mice developed glucose intolerance 
to a similar degree as GPR40/FFAR1 wild-type (WT) mice on a high-fat diet condition 
and diabetogenic KK gene background, so the lack of GPR40/FFAR1 does not 
exacerbate glucose intolerance and insulin resistance. Interestingly, glucose-induced 
insulin secretion under high palmitate concentration was significantly lower in KO than 
in WT islets, so GPR40/FFAR1 has a major role in regulating fatty acid-augmented 
insulin secretion. These findings indicate that loss of GPR40/FFAR1 function does not 
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contribute to induce or exacerbate diabetes, and especially GPR40/FFAR1 is selectively 
involved in fatty-acid-augmented insulin secretion. 
Some of the activities attributed to fatty acids are mediated through their 
interaction with a number of G-protein-coupled receptors. GPR40/FFFAR1, GPR84, and 
GPR120 are activated by medium- to long-chain fatty acids (32), so it was speculated 
that these receptors might have compensatory activities in lack of GPR40/FFFAR1 
condition in vivo. I reasoned that because the high-fat diet used in this in vivo 
experiment contained not only saturated fatty acids but also unsaturated fatty acids, it 
might not be selective condition for GPR40/FFFAR1. Recently, it has been reported that 
GPR40/FFFAR1 deficiency protected from CLA (conjugated linoleic acid)-induced 
insulin resistance and hepatic steatosis, which suggested that GPR40/FFAR1 deficiency 
might link with the lack of CLA-induced augmentation of insulin secretion and 
GPR40/FFAR1 selectively resposense to the selective ligand of GPR40/FFAR1, linoleic 
acid, in vivo (72). Indeed, CLAs directly stimulate insulin secretion through 
GPR40/FFAR1 (73).  
In the second chapter, the function of GPR40/FFAR1 transgenic (Tg) mice which human 
GPR40/FFAR1 gene was overexpressed by using insulin II promoter was analysed. In 
comparison with nontransgenic (NonTg) littermates, GPR40/FFAR1 Tg mice showed 
the improvement of glucose tolerance with augmented insulin secretion on a high-fat 
diet condition and diabetogenic KK gene background. Isolated islets from 
hGPR40/FFAR1-Tg mice enhanced robust insulin secretion in response to high glucose 
without change of that in low glucose stimulation. In addition, hGPR40/FFAR1-Tg islets 
significantly increased insulin secretion against a naturally occurring agonist palmitate 
in the presence of glucose. These results indicate that GPR40/FFAR1 have a role in 
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regulating glucose-stimulated insulin secretion in vitro and plasma glucose levels in vivo, 
but its detailed mechanism has not been clarified yet. GPR40/FFAR1 activation by fatty 
acids stimulated the Gαq-PLC signaling pathway, resulting in the activation of PLC, 
production of IP3, and activation of DAG which leads to release of calcium from the 
endoplasmic reticulum (29, 32-34). Glucose and fatty acids could also augment insulin 
secretion through pathways involving PKC (63, 64). Recently, it has been reported that 
GPR40/FFAR1 signaling activated enhances GSIS pathway via dual potentiating 
mechanisms in which IP3 amplifies glucose-induced Ca2+ oscillations and DAG/PKC 
augments downstream secretory mechanisms independent of Ca2+ oscillations(74). 
Fasiglifam (TAK‐875), an oral, highly potent and selective GPR40/FFAR1 agonist was 
developed as a first in class agent (75). Fasiglifam was effective in lowering plasma 
glucose levels in a 12 week phase 2 randomized, double‐blind, placebo control and 
active comparator (glimepiride) trial (76). Whereas concerns about liver safety arose 
and Fasiglifam clinical development program was terminated in phase 3 (77), my 
research could contribute to the drug discovery of Fasiglifam from rodents to human. 
In conclusion, GPR40/FFAR1 is concerned with overt increase in insulin 
secretion in the presence of elevated glucose such as during the postprandial period, and 
I clarified the physiological role of GPR40/FFAR1 in vivo with genetically modified 
anumals. These data supported the concept that GPR40/FFAR1 agonists might be 
effective insulin secretagogues for the treatment of type 2 diabetes with low risk of 
hypoglycemia. 
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